In a recent study published in The Lancet Respiratory Medicine, researchers reported the TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline, linezolid, and pretomanid (BPaL)-based regimens for pulmonary tuberculosis resistant to rifampicin.

In a recent review published in the Open Forum Infectious Diseases journal, researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.